Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 1, 2015, Pages 109-118

  Chowdhury, Sayan Mullick ^b   Surhland, Cassandra ^b   Sanchez, Zina ^a   Chaudhary, Pankaj ^c   Suresh Kumar, M A ^a   Lee, Stephen ^b   Peña, Louis A ^b,d   Waring, Michael ^e   Sitharaman, Balaji ^b   Naidu, Mamta ^f  

^a STONY BROOK UNIVERSITY   (United States)

^b St Francis Hospital The Heart Center   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d BROOKHAVEN NATIONAL LABORATORY   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apurinic endonuclease 1; CG 4; GBM; Graphene nanoribbons; Lucanthone; Rat glial progenitor cells; Thioxanthenones

Indexed keywords

CELL CULTURE; CELL DEATH; CONTROLLED DRUG DELIVERY; ENZYMES; GRAPHENE; GRAPHENE NANORIBBON; NANORIBBONS; RATS; TUMORS;

APURINIC ENDONUCLEASE; CG-4; GLIAL PROGENITORS; GRAPHENE NANORIBBONS; LUCANTHONE; THIOXANTHENONES;

TARGETED DRUG DELIVERY;

APURINIC ENDONUCLEASE 1; DEOXYRIBONUCLEASE I; GRAPHENE; GRAPHENE NANORIBBON; LUCANTHONE; NANORIBBON; UNCLASSIFIED DRUG; APEX1 PROTEIN, RAT; CARBON NANOTUBE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; GRAPHITE; OXYGEN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; EXCISION REPAIR; GLIA CELL; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; NONHUMAN; OXIDATION; PROTEIN EXPRESSION; STEM CELL; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CHEMISTRY; COCULTURE; CYTOLOGY; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; GLIA; METABOLISM; MOUSE; PH; RAT; TUMOR CELL LINE;

RATTUS;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; GLIOBLASTOMA; GRAPHITE; HUMANS; HYDROGEN-ION CONCENTRATION; LUCANTHONE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOTUBES, CARBON; NEOPLASM TRANSPLANTATION; NEUROGLIA; OXYGEN; RATS; STEM CELLS;

EID: 84919652808     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.08.001     Document Type: Article

References (28)

1. Bobola M.S., Finn L.S., Ellenbogen R.G., Geyer J.R., Berger M.S., Braga J.M., et al. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin Cancer Res 2005, 11:7405-7414.
2. Evans A.R., Limp-Foster M., Kelley M.R. Going APE over ref-1. Mutat Res 2000, 461:83-108.
3. Silber J.R., Bobola M.S., Blank A., Schoeler K.D., Haroldson P.D., Huynh M.B., et al. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 2002, 8:3008-3018.
4. Naidu M.D., Mason J.M., Pica R.V., Fung H., Pena L.P. Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. Jpn J Radiat Res 2010, 51:393-404.
5. Bobola M.S., Blank A., Berger M.S., Stevens B.A., Silber J.R. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001, 7:3510-3518.
6. Jiang Y., Guo C., Fishel M.L., Wang Z.-Y., Vasko M., Kelley M.R. Role of Ape1 in differentiated neurobalstoma SH- SY5Y cells in response to oxidative stress: Use of APE1 small molecule inhibitors to delineated APE1 functions 2009, 8(11):1273-1282.
7. Naidu M.D., Agarwal R., Pena L.A., Cunha L., Mezei M., Shen M., et al. Lucanthone and its derivative hycanthone inhibit apurinic endonuclease-1 (APE1) by direct protein binding. PLoS One 2011, 6:e23679.
8. Allen M.J., Tung V.C., Kaner R.B. Honeycomb carbon: A review of graphene. Chem Rev 2010, 110:132-145.
9. Zhang Y., Nayak T.R., Hong H., Cai W. Graphene: a versatile nanoplatform for biomedical applications. Nanoscale 2012, 4:3833-3842.
10. Chowdhury S.M., Kanakia S., Toussaint J.D., Frame M.D., Dewar A.M., Shroyer K.R., et al. In vitro hematological and in vivo vasoactivity assessment of dextran functionalized graphene. Sci Rep 2013, 3:2584.
11. Kanakia S., Toussaint J.D., Chowdhury S.M., Lalwani G., Tembulkar T., Button T., et al. Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent. Int J Nanomedicine 2013, 8:2821-2833.
12. Kim Y.K., Kim M.H., Min D.H. Biocompatible reduced graphene oxide prepared by using dextran as a multifunctional reducing agent. Chem Commun 2011, 47:3195-3197.
13. Liu Z., Robinson J.T., Sun X., Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc 2008, 130:10876-10877.
14. Robinson J.T., Tabakman S.M., Liang Y., Wang H., Casalongue H.S., Vinh D., et al. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J Am Chem Soc 2011, 133:6825-6831.
15. Sun X., Liu Z., Welsher K., Robinson J.T., Goodwin A., Zaric S., et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203-212.
16. Kosynkin D.V., Higginbotham A.L., Sinitskii A., Lomeda J.R., Dimiev A., Price B.K., et al. Longitudinal unzipping of carbon nanotubes to form graphene nanoribbons. Nature 2009, 458:872-876.
17. Mullick Chowdhury S., Lalwani G., Zhang K., Yang J.Y., Neville K., Sitharaman B. Cell specific cytotoxicity and uptake of graphene nanoribbons. Biomaterials 2013, 34:283-293.
18. van Engeland M., Nieland L.J.W., Ramaekers F.C.S., Schutte B., Reutelingsperger C.P.M. Annexin V-Affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998, 31:1-9.
19. Zhou J., Atsina K.B., Himes B.T., Strohbehn G.W., Saltzman W.M. Novel delivery strategies for glioblastoma. Cancer J 2012, 18:89-99.
20. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles delivery drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003, 20:409-416.
21. Kircher M.F., Mahmood U., King R.S., Weissleder R., Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003, 63:8122-8125.
22. Saito R., Bringas J.R., McKnight T.R. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 2004, 64:2572-2579.
23. Zhang L.W., Monteiro-Riviere N.A. Mechanisms of quantum Dot nanoparticle cellular uptake. Toxicol Sci 2009, 110:138-155.
24. Zong W.-X., Thompson C.B. Necrotic death as a cell fate. Genes Dev 2006, 20:1-15.
25. Yang K., Zhang S., Zhang G., Sun X., Lee S.-T., Liu Z. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett 2010, 10:3318-3323.
26. Yang X., Wang Y., Huang X., Ma Y., Huang Y., Yang R., et al. Multi-functionalized graphene oxide based anticancer drug-carrier with dual-targeting function and pH-sensitivity. J Mater Chem 2011, 21:3448-3454.
27. Qin X.C., Guo Z.Y., Liu Z.M., Zhang W., Wan M.M., Yang B.W. Folic acid-conjugated graphene oxide for cancer targeted chemo-photothermal therapy. J Photochem Photobiol B 2013, 120:156-162.
28. Heimberger A.B., Hlatky R., Suki D., Yang D., Weinberg J., Gilbert M., et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005, 11:1462-1466.